Business Context and Reporting Period
Company: Coherus BioSciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 23, 2016
Event: Entry into a Material Definitive Agreement for an underwritten public offering of common stock.
Key Financial Metrics
This filing reports on a capital raise event rather than operational financial performance. Key metrics related to the transaction include:
- Shares Issued: 3,500,000 shares of common stock.
- Offering Price: $18.00 per share.
- Over-Allotment Option: Underwriter granted a 30-day option to purchase up to 525,000 additional shares.
- Expected Net Proceeds: Approximately $60.1 million (base case) or approximately $69.1 million (if over-allotment is fully exercised).
- Underwriter: Barclays Capital Inc.
Note: The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes
The primary material change is the execution of an underwriting agreement to raise capital. The company expects to close the offering on May 26, 2016, subject to customary closing conditions. The shares are being issued pursuant to a shelf registration statement (File No. 333-208625) declared effective on January 21, 2016.
Outlook, Risks, and Management Commentary
Management Commentary: The company entered into the agreement to secure funding, with proceeds expected to be received net of estimated offering expenses. The transaction is structured with a standard 30-day over-allotment option.
Risks and Contingencies: The closing of the offering is contingent upon customary closing conditions. The filing incorporates by reference press releases (Exhibits 99.1 and 99.2) which may contain additional details on the use of proceeds or strategic outlook, though specific text is not included in this summary.
Investor Verification Checklist
- Verify the final closing date of the offering (expected May 26, 2016).
- Confirm whether the underwriter exercises the 30-day option to purchase the additional 525,000 shares.
- Review the attached Underwriting Agreement (Exhibit 1.1) for specific terms, conditions, and indemnification clauses.
- Examine the press releases (Exhibits 99.1 and 99.2) for the stated intended use of the net proceeds.
- Check subsequent filings for the actual net proceeds received after deducting final offering expenses.